Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders

Pär I Johansson; Sisse R Ostrowski

Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders

Afdeling for Klinisk Immunologi DIA

11 Citationer (Scopus)

Abstract

Recombinant activated factor VII (rFVIIa, NovoSeven) was introduced in 1996 for the treatment of hemophilic patients with antibodies against coagulation factor VIII or IX.

Originalsprog	Engelsk
Tidsskrift	Drug Design, Development and Therapy
Vol/bind	4
Sider (fra-til)	107-16
Antal sider	10
ISSN	1177-8881
Status	Udgivet - 1 jan. 2010

Andre filer og links

Link to publication in Scopus

Citationsformater

@article{a08226ab9d01464b8cd1696c59cbc3a3,

title = "Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders",

abstract = "Recombinant activated factor VII (rFVIIa, NovoSeven) was introduced in 1996 for the treatment of hemophilic patients with antibodies against coagulation factor VIII or IX.",

author = "Johansson, \{P{\"a}r I\} and Ostrowski, \{Sisse R\}",

year = "2010",

month = jan,

day = "1",

language = "English",

volume = "4",

pages = "107--16",

journal = "Drug Design, Development and Therapy",

issn = "1177-8881",

publisher = "Dove Medical Press Ltd",

}

TY - JOUR

T1 - Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders

AU - Johansson, Pär I

AU - Ostrowski, Sisse R

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Recombinant activated factor VII (rFVIIa, NovoSeven) was introduced in 1996 for the treatment of hemophilic patients with antibodies against coagulation factor VIII or IX.

AB - Recombinant activated factor VII (rFVIIa, NovoSeven) was introduced in 1996 for the treatment of hemophilic patients with antibodies against coagulation factor VIII or IX.

UR - https://www.scopus.com/pages/publications/79952025130

M3 - Journal article

C2 - 20689697

SN - 1177-8881

VL - 4

SP - 107

EP - 116

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

ER -

Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders

Abstract

Andre filer og links

Fingeraftryk

Citationsformater